Literature DB >> 30061944

EZH2 inhibition promotes methyl jasmonate-induced apoptosis of human colorectal cancer through the Wnt/β-catenin pathway.

Yao Wang1, Li Fan1, Chunguo Cui2, Yongkun Wang3, Tingting Liang4.   

Abstract

Methyl jasmonate potentially induces the differentiation of human myeloid leukemia cells and inhibits their proliferation; it may induce the differentiation and apoptosis of human lymphocytic leukemia cells, but does not exert a damaging effect on normal lymphocytes. In the present study, the anticancer effect of methyl jasmonate on human colorectal cancer cells was investigated. Cell viability and apoptosis was assessed using a Cell Counting kit-8 assay and flow cytometry, respectively. Methyl jasmonate suppressed cell viability and induced apoptosis in human colorectal cancer cells. Additionally, methyl jasmonate increased the activation of caspase-3, inhibited the expression levels of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) and the Wnt/β-catenin pathway in human colorectal cancer. Downregulation of EZH2 expression enhanced the anticancer effect of methyl jasmonate on human colorectal cancer cells through suppression of the Wnt/β-catenin pathway. Thus, EZH2 downregulation promotes the anticancer effect of methyl jasmonate by inducing apoptosis in human colorectal cancer cells through the Wnt/β-catenin pathway.

Entities:  

Keywords:  Wnt/β-catenin; enhancer of zeste 2 polycomb repressive complex 2 subunit; human colorectal cancer; methyl jasmonate

Year:  2018        PMID: 30061944      PMCID: PMC6063041          DOI: 10.3892/ol.2018.8779

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  A randomized clinical trial of synbiotic treatment before colorectal cancer surgery.

Authors:  Bojan Krebs; Matjaž Horvat; Andrej Golle; Zeljko Krznaric; Dino Papeš; Goran Augustin; Nuhi Arslani; Stojan Potrč
Journal:  Am Surg       Date:  2013-12       Impact factor: 0.688

2.  Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases: A Meta-analysis.

Authors:  Riom Kwakman; Anne M Schrama; Josefien P van Olmen; René H Otten; Elly S de Lange-de Klerk; Erienne M de Cuba; Geert Kazemier; Elisabeth A Te Velde
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

3.  Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients.

Authors:  Mulong Du; Sang Liu; Dongying Gu; Qiaoyan Wang; Lingjun Zhu; Meiyun Kang; Danni Shi; Haiyan Chu; Na Tong; Jinfei Chen; Tamara S Adams; Zhengdong Zhang; Meilin Wang
Journal:  Carcinogenesis       Date:  2014-09-19       Impact factor: 4.944

4.  Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity.

Authors:  Z Raviv; A Zilberberg; S Cohen; D Reischer-Pelech; C Horrix; M R Berger; R Rosin-Arbesfeld; E Flescher
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

5.  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Robert W Beart; Timothy F Wozniak; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini Soori; Janice F Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Saima Sharif; Mark S Roh; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2015-09-14       Impact factor: 13.506

6.  NGX6 inhibits cell invasion and adhesion through suppression of Wnt/beta-catenin signal pathway in colon cancer.

Authors:  Qin Guo; Shourong Shen; Mantian Liao; Ping Lian; Xiaoyan Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2010-06-13       Impact factor: 3.848

7.  Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.

Authors:  Yan-Long Liu; Xu Gao; Yang Jiang; Gan Zhang; Zi-Cheng Sun; Bin-Bin Cui; Yan-Mei Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-19       Impact factor: 4.553

8.  FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β.

Authors:  Chenxi Gao; Guangming Chen; Shih-Fan Kuan; Dennis Han Zhang; David D Schlaepfer; Jing Hu
Journal:  Elife       Date:  2015-09-03       Impact factor: 8.140

9.  Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.

Authors:  Li Ma; Xiaolin Wang; Tao Jia; Wei Wei; Mei-Sze Chua; Samuel So
Journal:  Oncotarget       Date:  2015-09-22

10.  SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.

Authors:  E Aranda; J Aparicio; V Alonso; X Garcia-Albeniz; P Garcia-Alfonso; R Salazar; M Valladares; R Vera; J M Vieitez; R Garcia-Carbonero
Journal:  Clin Transl Oncol       Date:  2015-12-15       Impact factor: 3.405

View more
  3 in total

1.  Methyl Jasmonate Cytotoxicity and Chemosensitization of T Cell Lymphoma In Vitro Is Facilitated by HK 2, HIF-1α, and Hsp70: Implication of Altered Regulation of Cell Survival, pH Homeostasis, Mitochondrial Functions.

Authors:  Yugal Goel; Saveg Yadav; Shrish Kumar Pandey; Mithlesh Kumar Temre; Vinay Kumar Singh; Ajay Kumar; Sukh Mahendra Singh
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

2.  Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma.

Authors:  Yong Wu; Yu Deng; Qinhao Guo; Jun Zhu; Lijie Cao; Xueqi Guo; Fei Xu; Weiwei Weng; Xingzhu Ju; Xiaohua Wu
Journal:  J Cell Mol Med       Date:  2019-05-22       Impact factor: 5.310

3.  Tumor Decelerating and Chemo-Potentiating Action of Methyl Jasmonate on a T Cell Lymphoma In Vivo: Role of Altered Regulation of Metabolism, Cell Survival, Drug Resistance, and Intratumoral Blood Flow.

Authors:  Yugal Goel; Saveg Yadav; Shrish Kumar Pandey; Mithlesh Kumar Temre; Babu Nandan Maurya; Ashish Verma; Ajay Kumar; Sukh Mahendra Singh
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.